Background: Molecular screening programs use next-generation sequencing (NGS) of cancer gene panels to analyze metastatic biopsies. We interrogated whether plasma could be used as an alternative to metastatic biopsies.
identified in either tumor or plasma; in nine patients, the same mutations was identified in tumor and plasma; in two patients, a mutation was identified in tumor but not in plasma; in two patients, a mutation was identified in plasma but not in tumor. Thus, in 13 of 17 (76%, 95% CI 50% to 93%) patients, tumor and plasma provided concordant results whereas in 4 of 17 (24%, 95% CI 7% to 50%) patients, the results were discordant, providing complementary information.
Conclusion
: Plasma can be prospectively tested as an alternative to metastatic biopsies in molecular screening programs. Key words: breast cancer, circulating tumor DNA, targeted gene sequencing, liquid biopsy introduction Breast cancer (BC) is the most frequent cancer diagnosed in women in Europe [1] and metastatic disease is considered to be largely incurable. Major advances in BC treatment involve targeted therapies such as tamoxifen for estrogen receptor (ER)-positive BC and trastuzumab for human epidermal growth factor (HER2)-positive BC. In these examples, a drug directed against a specific target was available.
International collaborative efforts such as The Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) have provided important insight into the mutational landscape of BC using next-generation sequencing (NGS) technologies [2, 3] . These efforts have led to a catalog of new potential targets for which available treatments may be tested in rationally designed clinical trials with built-in, molecular screening programs [4] .
This approach of personalizing treatment of patients with metastatic BC according to the results of molecular screening (comparative genomic hybridization and Sanger sequencing on selected genes) carried out on metastatic lesions biopsies was recently shown to be feasible in a multicenter setting, in the SAFIR01 trial [5] . However, several patients could not enter this program for the following reasons: nonaccessible metastatic lesions, bone disease only, not consenting to an invasive procedure and failed biopsies.
Recent advances in the detection and characterization of plasma cell-free DNA offer the hope that plasma can be a noninvasive means to monitor tumor genotype and treatment response, introducing the concept of 'liquid biopsy' [6, 7] . In most of the reported studies on plasma cell-free circulating tumor DNA (ctDNA), only a few mutations or genomic rearrangements per patient have been identified in the primary tumor that were then followed in plasma samples [8] [9] [10] . Recently, exome sequencing has been carried out directly on plasma samples [11] , but this approach is feasible only in cases with a high tumor burden and high levels of plasma ctDNA and it is not yet ready to be applied in molecular screening programs. In another study, Forshew et al. developed a tagged-amplicon deep sequencing (TAm-Seq) method to identify mutations for selected exons in six genes in plasma [12] . In contrast, molecular screening using tumor tissue often analyzes a much higher number of genes [13] .
To determine whether plasma can be used as an alternative to metastatic biopsies in molecular screening programs, we have carried out a pilot study using NGS for a commercially available 50-gene panel tested separately on tumor ( primary and/or metastatic) lesions and serial plasma samples totaling 100 samples from 17 patients with metastatic BC.
patients and methods

patient selection
Patients included in our pilot study needed to have histologically confirmed diagnosis of BC, progressive metastatic disease before starting a new line of treatment and accessible lesions for biopsy. All patients included in the study, underwent a biopsy of primary (in case of initially diagnosed metastatic disease) or metastatic lesion(s) and a blood draw for plasma isolation and for germline DNA extraction. Patients were also asked to consent for the use of previous available biopsies of primary and/or metastatic lesions. Moreover, patients were asked for additional blood draws for plasma isolation after one cycle of treatment and at disease progression. Patients and treating physicians were blinded to the results of this study and no treatment decisions were taken on the basis of these results. This study was part of a larger project to interrogate spatial and temporal heterogeneity in BC and was approved by the ethics committee (approval number CE1895) of the Jules Bordet Institute (Brussels, Belgium). All patients have provided written informed consent for participation in this study. 
somatic mutations profiling using the Ion Torrent technology
Somatic mutations (substitutions, insertions or deletions) were assessed using the Ion AmpliSeq™ Cancer Hotspot Panel v2, designed to amplify 207 amplicons covering ∼2800 COSMIC mutations from the 50 most commonly reported oncogenes and tumor suppressor genes (Ion Torrent, Life Technologies, Carlsbad, CA). Supplementary Table S1, available at Annals of Oncology online, provides the list of the 50 genes. Details about sequencing library preparation are provided in the supplementary material, available at Annals of Oncology online. The targeted average coverage for all tumor ( primary or metastases) samples and for germline DNA samples was ×1000 and for the plasma circulating DNA samples ×25 000, respectively. Data analysis and spiking experiments using cell-free DNA are provided in the supplementary material, available at Annals of Oncology online. The minimal coverage depth per amplicon to pass quality control and to allow for mutation calling is described in the supplementary material, available at Annals of Oncology online. The whole process was carried out at OncoDNA, Gosselies, Belgium under the ISO15189 accreditation to mimic a real-time diagnostic situation. 
confirmation of identified mutations
statistics
The sample size was calculated to estimate the proportion of patients with at least one detected mutation. With an anticipated mutation rate of 50%, a sample size of 17 patients would allow to calculate a 95% confidence interval (CI) of a width of 24%. The Clopper-Pearson method was used to estimate CIs. Mainly descriptive statistics were used throughout the paper.
results patients and samples
In this study, we have screened 21 patients and finally included 17 patients. Four (19%) patients were excluded because of failed metastatic biopsies due to low tumor cellularity (<10%) (supplementary Figure S1 , available at Annals of Oncology online). Among the 17 patients, 12 had estrogen receptor (ER)+/HER2−, 3 had HER2+ and 2 had ER−/HER2− tumors. These patients had received a median of three lines of chemotherapy (range 0-7) for metastatic disease prior to biopsy of the lesion and plasma sampling (Table 1 and supplementary Table S2 , available at Annals of Oncology online). Supplementary Table S3 , available at Annals of Oncology online provides sample annotation and characteristics for all samples analyzed in this study.
mutation analysis using the 50-cancer gene panel (Ion Torrent technology)
We have obtained evaluable NGS results from 60 of 69 tumor ( primary or metastasis) samples, from all 31 plasma samples and from all 17 normal DNA samples analyzed from 17 patients. The nine samples that were not evaluable by NGS were FFPE tumor blocks from the primary tumors from two patients collected more than 20 years ago. The actual median coverage for tumor tissue ( primary/metastasis) samples was ×1263 (range ×351-6669) and for plasma samples it was ×18 875 (range ×4163-65 357). Using this approach, we were able to detect mutations in plasma circulating DNA at allelic frequencies as low as 0.5% (supplementary Table S4 , available at Annals of Oncology online). The turnaround time from processing the plasma sample to final mutation data report was 7 days.
When using the 50-cancer gene panel in 60 tumor ( primary and/or metastases) samples from the 17 patients, 12 of 17 patients or 71% (95% CI 44% to 90%) had at least one mutation (median 1 mutation per patient, range 0-2 mutations) in either the p53, PIK3CA, PTEN, AKT1 or IDH2 gene ( Table 2, supplementary Table S4 , available at Annals of Oncology online). All mutations identified were substitutions. Analysis of multiple biopsies from the same metastatic lesion or multiple metastatic lesions at the same time-point from the same patient using the 50-cancer gene panel did not reveal additional mutations with the exception of patient 14 (Table 2) .
When using the same 50-gene panel in 31 plasma samples from the same 17 patients, 12 of 17 patients or 71% (95% CI 44% to 90%) had at least one mutation (median 1 mutation per patient, range 0-2 mutations) in either p53, PIK3CA, PTEN, AKT1, IDH2 and SMAD4 gene ( Table 2, supplementary Table S4 , available at Annals of Oncology online). All mutations identified were substitutions. Among the 12 patients with detectable mutations in the plasma, 7 had more than one plasma sample collected.
Among the 17 patients with evaluable NGS results, 3 ( patients 30, 38 and 11) had available primary tumor diagnosed 2, 8 and 20 years before the biopsy of the metastatic disease and plasma collection, respectively. In two of them, with the longer time interval between primary tumor diagnosis and tissue/ plasma collection ( patients 38 and 11), a PIK3CA and an AKT1 mutation, respectively, was detected in the metastatic biopsy and plasma sample but not in the primary tumor ( Table 2) . comparison between synchronous plasma and tumor lesions
To interrogate whether plasma ctDNA can recapitulate metastatic disease, we focused our analysis on matched plasma samples and tumor lesions from 17 patients collected at the same time-point during the disease course and analyzed them separately using the 50-gene panel. In four patients, no mutation was identified in either tumor or plasma; in nine patients, the same mutations were identified in tumor and plasma; in two patients, a mutation was identified in tumor but not in plasma; in two patients, a mutation was identified in plasma but not in tumor. Thus, in 13 of 17 (76%, 95% CI 50% to 93%) patients, tumor and plasma provided concordant results whereas in 4 of 17 (24%, 95% CI:7-50%) patients, the results were discordant, providing complementary information (Table 3, Figure 1 ). Interestingly, in both patients (10 and 39) with mutations detected in tumor but not in synchronous plasma using Ion Torrent, the mutations were detected in plasma samples using the Illumina technology (Table 3 and supplementary Table S4 , available at Annals of Oncology online).
Patients 3 and 20 were the two patients for whom a mutation was detected in plasma but not in synchronous tumor biopsy using the Ion Torrent. In patient 3, diagnosed with lobular ER +/HER2− BC, we observed in the plasma sample the co-existence of mutations in PTEN ( p.Q171E) and SMAD4 ( p.E394*) genes at allele frequencies of 25.9% and 10.9%, respectively. Biopsy of the liver metastasis at the same time-point identified only the PTEN mutation but not the mutation in the SMAD4 gene. This patient had multiple liver, bone and ovarian metastases, and ascites at the time of plasma collection. Patient 20 with ductal ER+/HER2− breast carcinoma had a PIK3CA mutation identified in plasma at an allele frequency of 14.3% but not in synchronous liver metastasis. This patient had multiple liver and bone metastases at the time of the plasma collection. These results were confirmed using the Illumina technology (supplementary Table S4 , available at Annals of Oncology online). They Rules for assigning samples as positive for a variant are described in the supplementary material, available at Annals of Oncology online. When patients had multiple metastases analyzed at the same time-point, the range of mutant allele frequency is provided for these samples. suggest that, in some cases, analysis of plasma samples might be more representative of the mutational spectrum of the metastatic disease than the single biopsy of a metastatic lesion.
discussion
Currently, molecular screening programs rely either on primary tumor or metastatic biopsies as a source for mutation detection [5, 14] . However, some metastatic BC patients cannot participate in such programs for one of several reasons: because no metastatic lesion is accessible for biopsy; they are unwilling to undergo an invasive procedure; or the metastatic biopsy itself does not contain tumor material of sufficient quantity/quality for downstream analysis. Plasma circulating DNA might be an attractive alternative to tumor tissue for the molecular characterization of metastatic disease [6, 7] . To our knowledge, this is the first study demonstrating the feasibility of performing high-coverage NGS for a 50-cancer gene panel in plasma samples from metastatic BC patients. Using the Ion Torrent technology, we were able to detect mutations in plasma circulating DNA at variant allele frequencies as low as 0.5%. Our results were confirmed using an alternative NGS technology (Illumina). Forshew et al. have developed the tagged-amplicon deep sequencing (TAm-Seq) method and were able to identify mutations for selected exons in six genes in plasma [12] .
Another approach to interrogate mutations in plasma circulating DNA uses exome sequencing [11] . However, today, exome sequencing in plasma DNA is only feasible in patients with high levels of circulating tumor DNA. Moreover, although it provides more information about the tumor genome compared with a targeted gene screen approach, it demands more sophisticated bioinformatics analysis. For the above reasons, this approach may not be widely applicable in a molecular screening program.
In contrast, other technologies such as beads, emulsion, amplification and magnetics (Beaming) [15] and digital PCR [16] can allow mutation detection in plasma circulating DNA at allele frequencies as low as 0.01% [7] but this is feasible only for a limited number of preselected mutations and is associated with substantial cost. Therefore, the digital PCR approach is better suited for monitoring few known mutations rather than for a molecular screening program. The approach of high-coverage NGS for a 50-cancer gene panel that we have used makes it possible to screen for mutations in a substantial number of the most well-known cancer genes in plasma circulating cell-free DNA at a reasonable cost, with a quick turnaround time (7 days from receiving plasma sample to final data) and may be the preferred approach for molecular screening programs.
When we compared matched plasma and tumor samples collected at the same time-point using the Ion Torrent, we observed concordant results for 13 of 17 (76%, 95% CI 50% to 93%) patients. The reason why a mutation was detected in tumor but not in synchronous plasma for two patients could be due to either the absence of this mutation in plasma DNA or to the presence of this mutation in allele frequencies below the detection limit of our method. Indeed, the latter seems to be the reason for these discordances in our series since, in both patients, the mutation was detected in plasma using the Illumina technology. For the two patients for whom a mutation was detected in plasma but not in synchronous metastasis, the mutant allele frequencies were high (12% and 14.3%, respectively) suggesting that these mutations might represent tumor clones not captured by the metastatic biopsy.
In a plasma sample from a patient with metastatic lobular cancer, we observed the co-occurrence of PTEN and SMAD4 loss-of-function mutations. To our knowledge, this is the first time that the co-occurrence of these two mutations is described in BC. Evidence of the biological significance of the co-occurrence of these mutations has been previously shown in prostate cancer [17] . Indeed, in PTEN null mouse models, the genetic deletion of SMAD4 was associated with the development of highly invasive and lethal prostate cancers with 100% penetrance [17] . Interestingly, in our study, the PTEN mutation was observed both in plasma and synchronous liver metastases whereas the SMAD4 mutation was observed only in the plasma at an allele frequency of 10.9%. Our results were independently validated using an alternative NGS technology. Thus, in some cases, plasma ctDNA might better capture tumor heterogeneity than the biopsy of a single metastatic lesion.
Moreover, using the 50-cancer gene panel, we have identified in two patients, the presence of 'actionable' mutations in the PIK3CA and AKT1 genes in synchronous plasma and metastases samples that we could not identify in primary tumors diagnosed 8 and 20 years before, respectively. Similarly, by comparing plasma ctDNA and archived tumor tissue DNA using Beaming for the three most common PIK3CA mutations, 
